Total buying$1.66M7 buys
RAPP
Rapport Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/25 to 10/25.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$539k5 sells
Net open-market+$1.12MBuying minus selling
Active insiders8Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 23, 2026
Open-market transaction mix · 12 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 2 | 0 | $0 | $331k | -$331k |
| Oct 2026 | 7 | 3 | 0 | $1.66M | $207k | $1.45M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (7)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- PM+$974.3k
- GC-$331.9k
- MJ+$248.9k
- CA-$207.7k
- IA+$143.6k
RAPP transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period12transactionstxns
- P · Open-market buys · dominant7 · 58%
- S · Open-market sells5 · 42%
Activity by reported role
A joint filing can contribute to multiple rolesDirector6
Chief executive officer3
COO2
Chief financial officer1
Reported Holdings After
Separated by insider, security, and ownership type
Ceesay AbrahamCommon Stock · Direct
450,035Oct 21, 2026
Gault CherylCommon Stock · Direct
139,914Sep 30, 2026
Maraganore JohnCommon Stock · Indirect · By John M. Maraganore Revocable Trust
9,411Oct 22, 2026
Ignelzi Troy A.Common Stock · Direct
15,500Oct 21, 2026
Paul Steven MCommon Stock · Indirect · By Paul Capital Strategy III Fund LLC
77,380Oct 22, 2026
Young Wendy B.Common Stock · Direct
13,289Oct 22, 2026
Silva Paul MCommon Stock · Indirect · By Paul M Silva 2016 Declaration of Trust U/A DTD 12/19/2016
3,680Oct 22, 2026
Sanchez RamiroCommon Stock · Direct
3,600Oct 23, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 25 → Oct 25
LessMore
Rapport Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Rapport Therapeutics, Inc.?
Ceesay Abraham, Sanchez Ramiro, Silva Paul M, Young Wendy B., PAUL STEVEN M, MARAGANORE JOHN, Ignelzi Troy A., Gault Cheryl.
When was the latest reported open-market purchase?
Sanchez Ramiro reported a buy on Oct 23, 2026 valued at $98.4k. Read the SEC filing.
When was the latest reported open-market sale?
Ceesay Abraham reported a sale on Oct 21, 2026 valued at $64.4k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $1,125,247.43. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.